Healthcare firm Micro Labs has unveiled a dextrose drug Hypotab to treat low blood sugar in diabetic patients. “Hypotab is meant for type two diabetes patients who suddenly face hypoglycaemia (low sugar) in the body and those who take insulin, which makes them prone to develop the symptom,” Micro Labs vice-president B.R. Srinath told reporters here at a preview of the drug. Priced economically, the carbohydrate drug, to be bought only on prescription by a qualified doctor, will restore normal blood glucose levels in diabetic patients soon after it is consumed. Hypotab is the first standardised therapy to treat low blood sugar and manufactured using the advanced technology of AbMax Biotechnology Co in China, as it offers 20 micron particle size for faster absorption in the body and gives quick relief,” said Srinath. The city-based pharma firm has invested Rs5.5 crore to set up the drug plant in Puducherry, with an installed capacity of one million tablets per month. The Rs1,646-crore company is targeting Rs4.2 crore revenue in this fiscal (2012-13) from Hypotab, Rs12 crore in next fiscal (2013-14) and Rs24 crore in 2014-15, as the market for treating low sugar remains untapped. From gulftoday
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor